Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
Andrea Lynne Harzstark
No relevant relationships to disclose
Tomasz M. Beer
No relevant relationships to disclose
Vivian K. Weinberg
No relevant relationships to disclose
Celestia S. Higano
No relevant relationships to disclose
Luke T. Nordquist
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Evan Y. Yu
No relevant relationships to disclose
Joanna Mi
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose